{
    "nctId": "NCT01305954",
    "briefTitle": "Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients",
    "officialTitle": "LCCC 1027: Expression Of P16INK4a As A Predictor Of Myelosuppression In Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Determine if p16INK4a Expression at Baseline is Related to Nadir Neutrophil Counts in Women with Breast Cancer Receiving Chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 18 years of age;\n* Histologically confirmed Stage I-IV breast cancer;\n* ECOG Performance Status 0-3;\n* Scheduled to start a new course of chemotherapy in the neo-adjuvant, adjuvant or metastatic setting for newly diagnosed or recurrent disease;\n* Growth factors, e.g., filgrastim, pegfilgrastim, are allowed, but their dose and duration will be tracked.\n* Absolute Lymphocyte Count (ALC) \\> 500 cells/\u03bcL as determined by routine CBC with differential;\n* Signed, IRB approved written informed consent.\n\nExclusion Criteria:\n\n* Presence of acute, active infection;\n* History of clonal bone marrow disorder (i.e., myelodysplastic or myeloproliferative disorder, acute or chronic leukemia);\n* Other co-morbid illness which would impair ability to participate in the study;\n* Concurrent experimental therapy (Note: concurrent biologic therapy IS permitted, provided it is not experimental).\n* Prior or current receipt of histone deacetylase (HDAC) inhibitors",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}